Clinical Summary: Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression
Women with postpartum depression often present with anxiety and insomnia alongside depressed mood, and these symptoms are linked to more severe illness, longer time to treatment response, impaired functioning, and increased self-harm ideation. This analysis asks whether a brief oral course of zuranolone improves that full symptom cluster quickly enough to matter in real-world postpartum care.
Key Findings
- Concurrent remission of depressive and anxiety symptoms favored zuranolone over placebo by day 3 and remained superior through day 45 using HDRS-17 total score ≤ 7 plus HARS total score ≤ 7: 18.9% vs 2.7% (P = .003) at day 3, 40.5% vs 19.2% (P = .007) at day 15, and 52.1% vs 23.2% (P < .001) at day 45.
- Sustained concurrent remission at both days 15 and 45 was higher with zuranolone, with odds ratio [95% CI] 6.2 [2.2 to 17.4] (P < .001) for combined HDRS-17/HARS criteria and 3.7 [1.5 to 8.9] (P = .003) for combined MADRS/HARS criteria.
- Anxiety/somatization symptoms improved rapidly with zuranolone on the HDRS-17 A/S subscale, with LS mean [SE; 95% CI] change from baseline of −3.8 [0.3; −4.5 to −3.2] vs −2.7 [0.3; −3.3 to −2.0] (P = .007) at day 3 and −5.7 [0.4; −6.4 to −5.0] vs −4.3 [0.4; −5.0 to −3.5] (P = .003) at day 45.
- At day 15, anxiety response rates were higher with zuranolone than placebo on clinician-rated measures: HARS response was 71.6% vs 49.3% (P = .007) and HDRS-17 A/S response was 68.9% vs 46.6% (P = .008).
- The benefit-risk profile was favorable on indirect metrics: NNT estimates (95% CI) were 5 [3 to 13] for HDRS-17 response and 5 [3 to 17] for remission at day 15, while NNH estimates were ≥ 10 for incidence of TEAEs and discontinuation due to an AE.
In women with postpartum depression, a once-daily, 14-day course of zuranolone produced rapid and sustained improvement in concurrent depression and anxiety, with additional benefit on insomnia symptoms and functional health. For postpartum depression with prominent anxiety or sleep disturbance, zuranolone offers a short-course option that can reduce the need for adding separate agents for those symptoms.
Practice Implications
- When treating postpartum depression with prominent anxiety, expect separation from placebo as early as day 3 for dual remission outcomes and anxiety/somatization symptoms, which is clinically relevant when rapid symptom relief is needed.
- Consider zuranolone particularly when postpartum depression is accompanied by insomnia symptoms, as nominally significant benefits versus placebo were observed on HDRS-17 Ins at all measured time points and on the MADRS reduced sleep item at all time points except day 21.
- Discuss treatment goals beyond mood alone: by day 45, zuranolone improved SF-36v2 Social Functioning, Mental Health, Physical Functioning, Role Physical, Bodily Pain, and the Mental Component Summary score versus placebo.
- Use the trial's indirect benefit-risk estimates to frame shared decision-making: NNT was 5 for day-15 HDRS-17 response and remission, and NNH estimates were ≥ 10 for incidence of TEAEs and discontinuation due to an AE.
